Related references
Note: Only part of the references are listed.Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy
Toby A. Eyre et al.
HAEMATOLOGICA (2019)
Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement
Gianluigi Reda et al.
HAEMATOLOGICA (2019)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia
Hongming Zhu et al.
BLOOD (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis
Hongming Zhu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system
Hong Wang et al.
BLOOD (2014)
Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
X. Niu et al.
LEUKEMIA (2014)
Extramedullary Disease in Acute Promyelocytic Leukemia: Two-In-One Disease
Francesco Albano et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2011)
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia
Jiong Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
S de Botton et al.
LEUKEMIA (2006)
All-trans retinoic acid/AS2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
ZX Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Share Paper
